Factor XII RNAi Composition for Thrombosis Control With Lower Bleeding Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thromboembolic events and hereditary angioedema are associated with a high risk of bleeding due to targeting enzymes downstream in the coagulation pathway, and there is a need for more effective and selective inhibition of Factor XII gene expression to prevent thrombosis and angioedema.
Innovation Solution
Development of novel RNA interference (RNAi) agents that specifically target and inhibit Factor XII gene expression, using sense and antisense strands with complementary sequences to reduce FXII levels, delivered via various methods including liposomes and targeting ligands to hepatocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anticoagulant treatments targeting downstream coagulation enzymes are used, then thromboembolic events are treated, but the risk of life-threatening hemorrhage increases
Solution Approach 1:
The invention extracts and targets the specific pathological factor (Factor XII) at the upstream initiation point of the coagulation cascade, rather than targeting downstream enzymes. This extraction approach allows selective inhibition of the harmful pathway while preserving other coagulation functions, thereby preventing thrombosis without significantly increasing bleeding risk.
Solution Approach 2:
The invention applies preliminary anti-action by inhibiting Factor XII expression before it can activate the coagulation cascade. Using RNAi technology, the patent prevents Factor XII from being translated into protein, thereby blocking the initiation of thrombosis before downstream pathological events occur, while avoiding interference with compensatory coagulation mechanisms.
2Reliability
If Factor XII is inhibited to prevent thrombosis, then thrombo-protective effect is achieved, but potential life-threatening hemorrhage risk is elevated
Solution Approach 1:
The invention applies local quality by delivering RNAi agents specifically to the liver using targeting ligands that recognize hepatocyte surface markers. This localized delivery ensures Factor XII suppression occurs primarily in the liver where Factor XII is synthesized, while maintaining normal coagulation function in other tissues, thereby achieving thromboprotection with minimal bleeding risk.
Solution Approach 2:
The invention uses liposome-based delivery systems and targeting ligands as intermediaries to transport RNAi agents to hepatocytes. These intermediaries enable selective delivery of the therapeutic agent to the site of Factor XII production, ensuring specific inhibition of hepatic Factor XII synthesis while preserving systemic coagulation homeostasis and minimizing hemorrhage risk.
3Measurement precision
If RNAi agents are delivered via liposomes with targeting ligands, then delivery precision to hepatocytes is improved, but device complexity increases
Solution Approach 1:
The invention segments the delivery system into distinct functional components: liposomes for cellular uptake, targeting ligands for hepatocyte-specific binding, and RNAi agents for genetic suppression. This segmentation allows each component to be optimized independently and facilitates controlled assembly, improving delivery precision while managing system complexity through modular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively inhibit FXII expression, providing prophylactic treatment for thrombosis and angioedema, reducing the risk of bleeding complications and offering therapeutic benefits for conditions like hereditary angioedema and venous thromboembolism.
Implementation Method 1
RNA interference (RNAi) agents for inhibition of Factor XII gene expression
Implementation Method 2
delivered via various methods including liposomes and targeting ligands to hepatocytes
Data Source
AI summary
RNA interference agents for inhibiting the expression of Factor XII (FXII) gene are described. Pharmaceutical compositions comprising one or more FXII RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo are also described. Delivery of the FXII RNAi agent(s) to liver cells in vivo provides for inhibition of FXII gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.